Oramed Pharmaceuticals Company Profile (NASDAQ:ORMP)

About Oramed Pharmaceuticals

Oramed Pharmaceuticals logoOramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company's products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ORMP
  • CUSIP:
Key Metrics:
  • Previous Close: $6.31
  • 50 Day Moving Average: $6.34
  • 200 Day Moving Average: $6.76
  • 52-Week Range: $5.70 - $10.51
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.12
  • P/E Growth: 0.00
  • Market Cap: $82.09M
  • Outstanding Shares: 13,283,000
  • Beta: 0.44
Profitability:
  • Return on Equity: -39.09%
  • Return on Assets: -27.40%
Debt:
  • Current Ratio: 6.45%
  • Quick Ratio: 6.45%
Additional Links:
Companies Related to Oramed Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Oramed Pharmaceuticals (NASDAQ:ORMP) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.00 (239.81% upside)

Analysts' Ratings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Show:
DateFirmActionRatingPrice TargetDetails
8/21/2016Rodman & RenshawReiterated RatingBuy$25.00View Rating Details
5/26/2016FBR & CoBoost Price TargetOutperform$15.00 -> $20.00View Rating Details
5/18/2016AegisReiterated RatingBuy$18.00View Rating Details
12/1/2015HC WainwrightBoost Price TargetBuy$24.00 -> $25.00View Rating Details
7/8/2015MLV & Co.Reiterated RatingBuyView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)
Current Year EPS Consensus Estimate: $-0.62 EPS
Next Year EPS Consensus Estimate: $-1.01 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.20)($0.20)($0.20)
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.22)($0.22)($0.22)
Q4 20161($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Insider Ownership Percentage: 25.90%
Institutional Ownership Percentage: 0.83%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2016Nadav KidronCEOBuy1,000$6.95$6,950.00View SEC Filing  
12/30/2015Miriam KidronCTOSell50,000$8.90$445,000.00View SEC Filing  
12/9/2015Michael BerelowitzDirectorSell700$9.44$6,608.00View SEC Filing  
12/8/2015Michael BerelowitzDirectorSell1,300$8.70$11,310.00View SEC Filing  
3/19/2015Nadav KidronCEOBuy2,600$3.88$10,088.00View SEC Filing  
9/11/2014Miriam KidronCTOSell31,699$8.41$266,588.59View SEC Filing  
9/10/2014Miriam KidronCTOSell23,000$8.40$193,200.00View SEC Filing  
9/4/2014Miriam KidronCTOSell8,301$9.41$78,112.41View SEC Filing  
6/6/2014Regals Capital Management LpMajor ShareholderBuy2,252$4.44$9,998.88View SEC Filing  
3/31/2014Michael BerelowitzDirectorSell9,434$10.50$99,057.00View SEC Filing  
3/25/2014Regals Capital Management Lpmajor shareholderBuy75,000$10.62$796,500.00View SEC Filing  
2/6/2014Regals Capital Management Lpmajor shareholderBuy51,292$15.61$800,668.12View SEC Filing  
7/10/2013Regals Capital Management LpMajor ShareholderBuy6,630$7.40$49,062.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Oramed Pharmaceuticals (NASDAQ:ORMP)
DateHeadline
seekingalpha.com logoHere's Where Oramed Fits Into The Diabetes Space (NASDAQ:ORMP)
seekingalpha.com - February 17 at 4:45 PM
News IconIs The Sell-Side Predicting That Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Will Move Higher? - Winfield Review (NASDAQ:ORMP)
winfieldreview.com - February 17 at 8:14 AM
gurufocus.com logoWhile Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever - GuruFocus.com (NASDAQ:ORMP)
www.gurufocus.com - February 9 at 8:13 PM
finance.yahoo.com logoWhile Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever (NASDAQ:ORMP)
finance.yahoo.com - February 9 at 8:13 PM
finance.yahoo.com logoOramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences (NASDAQ:ORMP)
finance.yahoo.com - February 7 at 9:05 AM
News IconAre Analysts Forecasting a Near-Term Upswing For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)? - Wall Street Beacon (NASDAQ:ORMP)
wsbeacon.com - February 1 at 8:12 PM
News IconEarnings According to Analysts for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)? - Aiken Advocate (NASDAQ:ORMP)
aikenadvocate.com - January 31 at 8:04 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Prospect Journal (NASDAQ:ORMP)
prospectjournal.com - January 31 at 12:48 AM
News IconEarnings in Full Force, Analysts Take Aim at Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Wall Street Beacon (NASDAQ:ORMP)
wsbeacon.com - January 27 at 6:04 AM
News IconIs Trouble Brewing For This Stock? Shares Gapping Lower: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Aiken Advocate (NASDAQ:ORMP)
aikenadvocate.com - January 25 at 5:54 AM
News IconUpside Alert: Delving into Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Prospect Journal (NASDAQ:ORMP)
prospectjournal.com - January 23 at 7:23 PM
News IconOramed Pharmaceuticals Inc. (ORMP) Valuation According To Analysts - UK Market News (NASDAQ:ORMP)
www.ukmarketnews.co.uk - January 21 at 7:57 AM
News IconGearing Up For a Bull Run? Analysts Weigh in on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Wall Street Beacon (NASDAQ:ORMP)
wsbeacon.com - January 20 at 4:45 AM
News IconConsensus Estimates on Earnings & Stock Price in Focus for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares - Aiken Advocate (NASDAQ:ORMP)
aikenadvocate.com - January 18 at 12:27 AM
investornewswire.com logoOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Strong Sell Recommendations At {RATING_CNT_STRONG_SELLS ... - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - January 16 at 9:25 AM
News IconWill The Needle Move For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ORMP)
wsbeacon.com - January 13 at 8:15 AM
News IconStock Edging Lower Out Of The Gate: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Wall Street Beacon (NASDAQ:ORMP)
wsbeacon.com - January 12 at 7:41 PM
finance.yahoo.com logoOramed reports 1Q loss - Yahoo Finance (NASDAQ:ORMP)
finance.yahoo.com - January 12 at 5:48 AM
sg.finance.yahoo.com logoOramed reports 1Q loss (NASDAQ:ORMP)
sg.finance.yahoo.com - January 12 at 5:48 AM
biz.yahoo.com logoORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:ORMP)
biz.yahoo.com - January 11 at 7:44 PM
investornewswire.com logoOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Strong Buy Recommendations At 2 - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - January 3 at 11:39 PM
247wallst.com logo3 Sleeper Biotechs That Could Bounce Back Strong in 2017 - 24/7 Wall St. (NASDAQ:ORMP)
247wallst.com - December 31 at 6:48 PM
investornewswire.com logoOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - December 26 at 9:46 AM
News IconCan This Stock Gain Traction: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Prospect Journal (NASDAQ:ORMP)
prospectjournal.com - December 20 at 1:28 PM
investornewswire.com logoCan Shares Of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Hit $30? - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - December 13 at 7:30 PM
News IconOramed Pharmaceuticals Inc. (ORMP) Under Analyst Spotlight - UK Market News (NASDAQ:ORMP)
www.ukmarketnews.co.uk - December 13 at 7:30 PM
openpr.com logoAntidiabetics Market Worth USD 80.0 Billion by 2022 (NASDAQ:ORMP)
www.openpr.com - December 8 at 7:30 PM
News IconShould You Buy Or Sell Oramed Pharmaceuticals Inc. (ORMP) On Analyst Concensus? - NewsDen (NASDAQ:ORMP)
newsden.net - December 7 at 9:28 AM
investornewswire.com logoBuy Calls Of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) At 0 - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - December 4 at 6:08 PM
News IconAnalysts Watch Oramed Pharmaceuticals Inc. (ORMP) And Issue New Targets - NewsDen (NASDAQ:ORMP)
newsden.net - December 3 at 6:14 PM
finance.yahoo.com logoORAMED PHARMACEUTICALS INC. Financials (NASDAQ:ORMP)
finance.yahoo.com - December 1 at 6:57 PM
4-traders.com logoOramed Pharmaceuticals : ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study (NASDAQ:ORMP)
www.4-traders.com - November 30 at 7:12 PM
finance.yahoo.com logoORMP: Oramed Reports Positive Phase Ib Data for ORMD-0901 (NASDAQ:ORMP)
finance.yahoo.com - November 30 at 7:12 PM
streetinsider.com logoOramed Pharma (ORMP) Completes ORMD-0901 Phase 1b; No Serious Adverse Events Noted - StreetInsider.com (NASDAQ:ORMP)
www.streetinsider.com - November 29 at 2:17 PM
finance.yahoo.com logoOramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study (NASDAQ:ORMP)
finance.yahoo.com - November 29 at 2:16 PM
finance.yahoo.com logo8:31 am Oramed Pharmaceuticals announces phase Ib study results of ORMD-0901 found it to be safe and well-tolerated (NASDAQ:ORMP)
finance.yahoo.com - November 29 at 2:16 PM
biz.yahoo.com logoORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report (NASDAQ:ORMP)
biz.yahoo.com - November 25 at 11:55 AM
News IconSpot Check on Stock With Abnormal Activity Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - CSZ News (NASDAQ:ORMP)
cincysportszone.com - November 23 at 6:54 PM
News IconSteering Attention Towards Earnings; Analysts Weigh in on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock - CSZ News (NASDAQ:ORMP)
cincysportszone.com - November 22 at 6:51 PM
investornewswire.com logoCan Shares Of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Smash $30? - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - November 22 at 11:01 AM
News IconOramed Pharmaceuticals, Inc. ORMP Financial and Strategic SWOT Analysis Review Prices from USD $125 (NASDAQ:ORMP)
www.bioportfolio.com - November 21 at 11:58 AM
4-traders.com logoOramed: Chinese partner building plant for our product (NASDAQ:ORMP)
www.4-traders.com - November 19 at 6:46 PM
investorplace.com logo17 Pharmaceuticals Stocks to Sell Now - Investorplace.com (NASDAQ:ORMP)
investorplace.com - November 18 at 6:17 PM
News IconOramed: Chinese partner building plant for our product - Globes (NASDAQ:ORMP)
www.globes.co.il - November 17 at 6:23 PM
investornewswire.com logoCan Shares Of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Get To $30? - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - November 15 at 7:19 PM
News IconSell-side is Weighing in on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Earnings & Targets - CSZ News (NASDAQ:ORMP)
cincysportszone.com - November 15 at 7:18 PM
News IconBroker Changes For Oramed Pharmaceuticals Inc. (ORMP) - NewsDen (NASDAQ:ORMP)
newsden.net - November 6 at 11:17 AM
investornewswire.com logoOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Buy Calls At 0 - Investor Newswire (NASDAQ:ORMP)
www.investornewswire.com - November 1 at 6:58 PM
News IconSell-side Consensus Sees Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Going Where Near-Term? - CSZ News (NASDAQ:ORMP)
cincysportszone.com - November 1 at 6:58 PM
News IconMarching Higher Late Morning are These Shares: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - CSZ News (NASDAQ:ORMP)
cincysportszone.com - October 28 at 6:27 PM

Social

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Where is Oramed Pharmaceuticals' stock going? Where will Oramed Pharmaceuticals' stock price be in 2017?

3 equities research analysts have issued twelve-month target prices for Oramed Pharmaceuticals' stock. Their forecasts range from $18.00 to $25.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $21.00 in the next year.

How do I buy Oramed Pharmaceuticals stock?

Shares of Oramed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Oramed Pharmaceuticals stock cost?

One share of Oramed Pharmaceuticals stock can currently be purchased for approximately $6.18.

Oramed Pharmaceuticals (NASDAQ:ORMP) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Earnings History Chart

Earnings by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Dividend History Chart

Dividend Payments by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Last Updated on 2/24/2017 by MarketBeat.com Staff